Wave Life Sciences Ltd. (WVE) Company Profile & Statistics

Wave Life Sciences Ltd.
WVE
(Nasdaq - US)
Open
13.34
-0.33 (-2.41%)
in:usd•As of: Nov 18, 2024 12:45 UTC -5
Open
13.75
High
13.78
Low
13.34

About Wave Life Sciences Ltd.

CEO

Paul B. Bolno

Headquarters

7 straits view #12-00, marina one east tower

singapore, u0 018936, singapore

Auditor

KPMG LLP

Employees

268

Share Holders

Website

www.wavelifesciences.com

Industry

biotechnology

Sector

health technology

Company Overview

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.

Wave Life Sciences Ltd. Statistics

Valuation Measures

Market Capitalization ²	2.03B
Enterprise Value	1.72B
Enterprise Value/EBITDA (ttm)	-12.02
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	12.04
Price to Sales (ttm)	18.87
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-66.50%
Profit Margin (ttm)	82.72%
Return on Equity (ttm)	-280.57%
Return on Invested Capital (ttm)	737.94%
Return on Assets (ttm)	-52.90%

Income Statement

Revenue (ttm)	53.61M
Revenue Per Share (ttm)	0.35
Gross Profit (ttm)	53.61M
EBITDA (ttm)³	-143.36M
Net Income Avi to Common (ttm)	-142.26M
Diluted EPS (ttm)	-1.11

Share Statistics

Beta (5Y Monthly)	-1.20
52-Week Change	156.54%
S&P500 52-Week Change	29.66%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	152.52M
Dividend Yield	0.00%
Float ⁴	108.14M
% Held by Insiders	29.10%
% Held by Institutions	89.73%

Balance Sheet

Total Cash (mrq)	310.95M
Total Cash Per Share (mrq)	2.04
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	1.90%
Quick Ratio (mrq)	1.90%
Book Value Per Share (mrq)	0.95

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.81
Free Cash Flow (ytd)	-108.23M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Wave Life Sciences Ltd.

Trade With A Regulated Broker